considerations for duration and de-escalation of immunotherapy in lung cancer
Published 2 years ago • 180 plays • Length 2:54Download video MP4
Download video MP3
Similar videos
-
2:28
optimal duration of immunotherapy administration for patients with nsclc
-
2:33
immunotherapy for lung cancer: current landscape and challenges
-
1:19
developments in immunotherapy for lung cancer
-
53:09
de-escalation in cancer care by kevin knopf, md
-
1:20
the crossroads of targeted therapy and immunotherapy in lung cancer
-
2:31
differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy
-
36:55
immunotherapy in lung cancer: rationale, evidence, and implications for the multidisciplinary team
-
4:15
the toxicities associated with immunotherapy in lung cancer patients
-
2:01
unanswered questions on immunotherapy for lung cancer
-
2:44
advances in perioperative immunotherapy in lung cancer
-
1:06:23
immunotherapy in lung cancer: rationale, evidence, and implications for the multidisciplinary team
-
2:28
how to monitor and manage immunotherapy related events in lung cancer
-
3:43
immunotherapy for operable lung cancer
-
59:24
marking new milestones with immunotherapy in locally advanced and early lung cancer
-
1:24
dr. chaft on considerations for restarting immunotherapy in lung cancer
-
17:37
managing adverse effects with immunotherapy
-
3:46
understanding immunotherapy for lung cancer
-
3:02
neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer
-
1:27
next steps in breast cancer: de-escalation & immunotherapy